Jade Biosciences registers Phase 3 EVERGREEN trial of JADE101 in IgA nephropathy
The study, sponsored by Jade Biosciences, is recruiting adults with IgA nephropathy to test subcutaneous JADE101 against placebo.
Jade Biosciences had one notable registry update this week.
- A Phase 3 trial called the "EVERGREEN Study" (NCT07902817) is recruiting participants to test JADE101 given by subcutaneous injection against placebo in adults with IgA Nephropathy (IgAN)1. The study plans to enroll 480 participants (estimated)1 and its primary outcome is the effect of JADE101 on Urine Protein Creatinine Ratio (UPCR), measured as change from baseline at Week 521.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.